Nanoparticle-based antigen favors high level of humoral immune responses and increases antigenicity of highly glycosylated protein.

Nanoparticles (NPs) have shown great potential as advanced vaccines and immunotherapy platforms due to their size and polyvalent epitopes. However, the immune responses elicited by glycosylated antigens conjugated to NPs with variable antigen densities remain poorly understood. In this study, we analyzed the glycosylation profile of the CD2v ectodomain (ED) of African swine fever virus, identifying 14 potential N-glycosylation sites (PNGS) among 192 residues, which markedly reduced its antigenicity. To enhance the antigenicity of CD2v, we designed three protein-based NPs derived from Ferritin, porcine circovirus type 2 (PCV2) capsid protein, and AP205 coat protein. Antigens were conjugated to the NP surfaces using the SpyTag/SpyCatcher system. Immunoassays demonstrated that these NPs rapidly induced higher levels of antigen-specific IgG compared to unconjugated antigens, with the effect being most pronounced for the highly glycosylated CD2v. All NPs significantly promoted IgG2a production, indicating a Th1-biased immune response. Furthermore, PCV2 NP reached the popliteal lymph node (PLN) within 5 min post-injection and persisted for 21 days, extensively interacting with B cells. These findings provide the potential of tailoring NP design to enhance antigenicity, providing a foundation for developing glycosylated antigen-targeted vaccines and immunotherapies.

• Publication year

  2025

• Venue

  International Journal of Biological Macromolecules

• Publication date

  2025-09-01

• Fields of study

  Medicine, Materials Science

• Identifiers
  DOI 10.1016/j.ijbiomac.2025.147967PMID 41022235
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Combination of S1-N-Terminal and S1-C-Terminal Domain Antigens Targeting Double Receptor-Binding Domains Bolsters Protective Immunity of a Nanoparticle Vaccine against Porcine Epidemic Diarrhea Virus.

  2024cited by this paper
• Cloning and expression of UbiA human gene using innovative methodologies for recombinant protein production in PUAST vector

  2024cited by this paper
• Nanovaccines: An effective therapeutic approach for cancer therapy.

  2023cited by this paper
• Size-Dependent In Vivo Transport of Nanoparticles: Implications for Delivery, Targeting, and Clearance.

  2023cited by this paper
• The ligand interactions of B cell Siglecs are involved in the prevention of autoimmunity to sialylated self-antigens and in the quality control of signaling-competent B cells.

  2023cited by this paper
• B cell receptor signaling in germinal centers prolongs survival and primes B cells for selection

  2023cited by this paper
• Engineered Norovirus-Derived Nanoparticles as a Plug-and-Play Cancer Vaccine Platform.

  2023cited by this paper
• Therapeutic induction of antigen-specific immune tolerance

  2023cited by this paper
• Glycans in HIV-1 vaccine design - engaging the shield.

  2022cited by this paper
• A systematic review of genotypes and serogroups of African swine fever virus

  2022cited by this paper
• Glycan shield of the ebolavirus envelope glycoprotein GP

  2022cited by this paper
• Nanoparticle-induced immune response: Health risk versus treatment opportunity?

  2022cited by this paper
• A modular and self-adjuvanted multivalent vaccine platform based on porcine circovirus virus-like nanoparticles

  2022cited by this paper
• Porcine Circovirus Type 2 Vaccines: Commercial Application and Research Advances

  2022cited by this paper
• In situ structure and dynamics of an alphacoronavirus spike protein by cryo-ET and cryo-EM

  2022cited by this paper
• Development of a synthetic nanoparticle vaccine presenting the HIV-1 envelope glycoprotein

  2022cited by this paper
• Nanotechnology‐facilitated vaccine development during the coronavirus disease 2019 (COVID‐19) pandemic

  2022cited by this paper
• Nanoparticle classification, physicochemical properties, characterization, and applications: a comprehensive review for biologists

  2022cited by this paper
• Protein-based antigen presentation platforms for nanoparticle vaccines

  2021cited by this paper
• The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization

  2021cited by this paper
• A glycan gate controls opening of the SARS-CoV-2 spike protein

  2021cited by this paper
• Adenovirus Core Proteins: Structure and Function

  2021cited by this paper
• The High Immunity Induced by the Virus-Like Particles of Foot-and-Mouth Disease Virus Serotype O

  2021cited by this paper
• Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates

  2021cited by this paper
• Neutralization Mechanism of a Monoclonal Antibody Targeting a Porcine Circovirus Type 2 Cap Protein Conformational Epitope

  2020cited by this paper
• Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice

  2020cited by this paper
• Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity

  2020cited by this paper
• Nimotuzumab Site-Specifically Labeled with 89Zr and 225Ac Using SpyTag/SpyCatcher for PET Imaging and Alpha Particle Radioimmunotherapy of Epidermal Growth Factor Receptor Positive Cancers

  2020cited by this paper
• Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses

  2020cited by this paper
• New Technologies for Influenza Vaccines

  2020cited by this paper
• A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses

  2020cited by this paper
• Overcoming Symmetry Mismatch in Vaccine Nanoassembly through Spontaneous Amidation

  2020cited by this paper
• Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

  2020cited by this paper
• Glycan-Modified Virus-Like Particles Evoke T Helper Type 1-Like Immune Responses.

  2020cited by this paper
• A Vaccine Displaying a Trimeric Influenza-A HA Stem Protein on Capsid-Like Particles Elicits Potent and Long-Lasting Protection in Mice

  2020cited by this paper
• Enhancing glycan occupancy of soluble HIV-1 envelope trimers to mimic the native viral spike

  2020cited by this paper
• Major swine viral diseases: an Asian perspective after the African swine fever introduction

  2020cited by this paper
• Site-specific glycan analysis of the SARS-CoV-2 spike

  2020cited by this paper
• Shaping humoral immunity to vaccines through antigen-displaying nanoparticles.

  2020cited by this paper
• Vulnerabilities in coronavirus glycan shields despite extensive glycosylation

  2020cited by this paper
• Self-assembly into virus–like particles of the recombinant capsid protein of porcine circovirus type 3 and its application on antibodies detection

  2020cited by this paper
• Genetic engineering strategies for construction of multivalent chimeric VLPs vaccines

  2020cited by this paper
• The Ebola virus glycoprotein and its immune responses across multiple vaccine platforms

  2020cited by this paper
• Self-Antigens Displayed on Liposomal Nanoparticles above a Threshold of Epitope Density Elicit Class-Switched Autoreactive Antibodies Independent of T Cell Help

  2019cited by this paper
• The Mechanistic Impact of N-Glycosylation on Stability, Pharmacokinetics, and Immunogenicity of Therapeutic Proteins.

  2019cited by this paper
• Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen.

  2019cited by this paper
• Ferritin nanoparticle-based SpyTag/SpyCatcher-enabled click vaccine for tumor immunotherapy.

  2019cited by this paper
• Nanovaccine: A novel approach in immunization

  2019cited by this paper
• Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus

  2019cited by this paper
• Self-Assembling Nanoparticles Usher in a New Era of Vaccine Design.

  2019cited by this paper
• Structural roles of PCV2 capsid protein N-terminus in PCV2 particle assembly and identification of PCV2 type-specific neutralizing epitope

  2019cited by this paper
• The long road to protect infants against severe RSV lower respiratory tract illness

  2019cited by this paper
• The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template

  2019cited by this paper
• Exploitation of glycosylation in enveloped virus pathobiology

  2019cited by this paper
• The 3.1-Angstrom Cryo-electron Microscopy Structure of the Porcine Epidemic Diarrhea Virus Spike Protein in the Prefusion Conformation

  2019cited by this paper
• Human Papillomavirus Vaccine Effectiveness Against HPV Infection: Evaluation of One, Two, and Three Doses.

  2019cited by this paper
• Global trends in infectious diseases of swine

  2018cited by this paper
• B Cells Are the Dominant Antigen‐Presenting Cells that Activate Naive CD4+ T Cells upon Immunization with a Virus‐Derived Nanoparticle Antigen

  2018cited by this paper
• Screening and identification of B-cell epitopes within envelope protein of tembusu virus

  2018cited by this paper
• Mutation in the VP2 gene of P1-2A capsid protein increases the thermostability of virus-like particles of foot-and-mouth disease virus serotype O

  2018cited by this paper
• Engineering a Rugged Nanoscaffold To Enhance Plug-and-Display Vaccination

  2018cited by this paper
• Structure of the Lassa virus glycan shield provides a model for immunological resistance

  2018cited by this paper
• Interactions Between Nanoparticles and Dendritic Cells: From the Perspective of Cancer Immunotherapy

  2018cited by this paper
• Structural analysis of glycoproteins: building N-linked glycans with Coot

  2018cited by this paper
• Glycan Shielding and Modulation of Hepatitis C Virus Neutralizing Antibodies

  2018cited by this paper
• Porcine parvovirus capsid protein expressed in Escherichia coli self‐assembles into virus‐like particles with high immunogenicity in mice and guinea pigs

  2017cited by this paper
• Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine

  2017cited by this paper
• Identification and Comparison of Receptor Binding Characteristics of the Spike Protein of Two Porcine Epidemic Diarrhea Virus Strains

  2016cited by this paper
• Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization

  2016cited by this paper
• Assembly, Engineering and Applications of Virus-Based Protein Nanoparticles.

  2016cited by this paper
• Bacterial superglue enables easy development of efficient virus-like particle based vaccines

  2016cited by this paper
• Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein

  2016cited by this paper
• Orchestrating immune responses: How size, shape and rigidity affect the immunogenicity of particulate vaccines.

  2016cited by this paper
• Generation of E. coli-derived virus-like particles of porcine circovirus type 2 and their use in an indirect IgG enzyme-linked immunosorbent assay

  2016cited by this paper
• Virus-like particles as drug delivery vectors.

  2016cited by this paper
• Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles

  2016cited by this paper
• Virus Like Particles as Immunogens and Universal Nanocarriers.

  2015cited by this paper
• Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140

  2015cited by this paper
• Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers.

  2015cited by this paper
• Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies

  2015cited by this paper
• African swine fever virus CD2v and C-type lectin gene loci mediate serological specificity.

  2015cited by this paper
• The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors

  2015cited by this paper
• An Overview of Pathogen Recognition Receptors for Innate Immunity in Dental Pulp

  2015cited by this paper
• Comparative Analysis of African Swine Fever Virus Genotypes and Serogroups

  2015cited by this paper
• Clinical, virological, immunological and pathological evaluation of four porcine circovirus type 2 vaccines.

  2014cited by this paper
• In vivo quantification of lymph viscosity and pressure in lymphatic vessels and draining lymph nodes of arthritic joints in mice

  2014cited by this paper
• Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies

  2013cited by this paper
• Porcine circovirus type 2 (PCV2): pathogenesis and interaction with the immune system.

  2013cited by this paper
• A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies

  2013cited by this paper
• Key roles of adjuvants in modern vaccines

  2013cited by this paper
• A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization

  2013cited by this paper
• Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin

  2012cited by this paper
• Emerging and re-emerging swine viruses.

  2012cited by this paper
• Processing and Localization of the African Swine Fever Virus CD2v Transmembrane Protein

  2011cited by this paper
• Norovirus vaccine against experimental human Norwalk Virus illness.

  2011cited by this paper
• The 2.3-Angstrom Structure of Porcine Circovirus 2

  2011cited by this paper
• Immunological mechanisms of vaccination

  2011cited by this paper
• The Hepatitis C Virus Glycan Shield and Evasion of the Humoral Immune Response

  2011cited by this paper
• Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns

  2010cited by this paper
• Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems.

  2010cited by this paper

• No citing papers are available for this paper.